Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
167.77
+0.70 (+0.42%)
Products, Regulatory, Other Pre-Announcement

Johnson & Johnson Announces Its First Phase 3 Covid-19 Vaccine Trial Ensemble Is Fully Enrolled

Published: 12/18/2020 02:24 GMT
Johnson & Johnson (JNJ) - Johnson & Johnson Announces Its First Phase 3 Covid-19 Vaccine Trial Ensemble is Fully Enrolled.
Phase 3 Trial (ensemble) of Investigational Janssen Covid-19 Single-dose Vaccine Candidate is Fully Enrolled With About 45,000 Participants.
Nterim Data From Ensemble Trial Currently Anticipated by End of Jan 2021.
Expects to Submit an Emergency Use Authorization Application to the U.S. Food and Drug Administration (fda) in February.
Phase 3 Clinical Trial to Explore Two-dose Regimen of Janssen’s Covid-19 Vaccine Candidate is Ongoing.